Our Pipeline

ADIENNE aims to establish BEGESAND® (INN: begelomab®) as the standard first-line treatment for acute Graft-versus-Host Disease (aGvHD) — a severe and life-threatening condition caused by the reaction of donor immune cells against the recipient’s tissue antigens (alloreaction). Currently, there is no approved therapy and no universally accepted standard of care for this disease.

BEGESAND® is a monoclonal antibody targeting CD26 (dipeptidyl peptidase IV, DPP4) and has been granted Orphan Drug Designation (ODD) by the FDA, EMA, and Switzerland for the treatment of aGvHD.

ADIENNE has recently completed a Phase II clinical trial to confirm the efficacy and safety of the product in such indication.

is a part of ADIENNE’s antibody–drug conjugate pipeline, a class of biopharmaceuticals designed to deliver cytotoxic payloads directly to cancer cells.

The drug is on development for the treatment of acute T-cell lymphoblastic leukemia (T-ALL), an aggressive cancer with very limited treatment options for patients whose disease relapses or resists standard therapies.

This antibody-based molecular platform enables the selective delivery of a potent cytotoxic agent to malignant cells, thereby enhancing efficacy while minimizing systemic toxicity.

is a part of ADIENNE’s indole derivatives small-molecule pipeline, a novel immunomodulatory approach for the management of checkpoint inhibitor–related toxicities.

The drug is under development for the treatment of immune dysreactive disorders, including inflammatory and infectious diseases.

An Orphan Drug Designation (ODD) for the treatment of primary CTLA-4 checkpoint–related immunodeficiencies, has been granted by EMA.

Biocompatible polymer nanoparticles (NPs) offer an effective platform for the immobilization of various enzymes, enhancing their stability, preserving their catalytic activity, and enabling their intravenous administration—an essential feature for enzyme replacement therapies (ERTs).

These therapies are particularly relevant in the treatment of lysosomal storage diseases (LSDs), a group of inherited metabolic disorders caused by deficiencies of lysosomal enzymes, which lead to the accumulation of undegraded substrates within the lysosome.

This pathological storage process results in a wide range of clinical manifestations, depending on the specific substrate involved and the site of accumulation. Representative examples of LSDs include mucopolysaccharidoses, mucolipidoses, oligosaccharidoses, Pompe disease, Gaucher disease, Fabry disease, Niemann–Pick disorders, and neuronal ceroid lipofuscinoses.